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Dual Delivery of EPO and BMP2 from a Novel
Modular Poly-e-Caprolactone Construct to Increase
the Bone Formation in Prefabricated Bone Flaps
Janki Jayesh Patel, MS,1 Jane E. Modes,1 Colleen L. Flanagan, MSE,1
Paul H. Krebsbach, DDS, PhD,2 Sean P. Edwards, DDS, MD,3 and Scott J. Hollister, PhD1
Poly-e-caprolactone (PCL) is a biocompatible polymer that has mechanical properties suitable for bone tissue
engineering; however, it must be integratedwith biologics to stimulate bone formation. Bonemorphogenetic protein-
2 (BMP2) delivered from PCL produces bone when implanted subcutaneously, and erythropoietin (EPO) works
synergistically with BMP2. In this study, EPO and BMP2 are adsorbed separately on two 3D-printed PCL scaffold
modules that are assembled for codelivery on a single scaffold structure. This assembled modular PCL scaffold with
dual BMP2 and EPO delivery was shown to increase bone growth in an ectopic location when compared with BMP2
delivery along a replicate scaffold structure. EPO (200 IU/mL) and BMP2 (65mg/mL) were adsorbed onto the outer
and inner portions of a modular scaffold, respectively. Protein binding and release studies were first quantified.
Subsequently, EPO+BMP2 and BMP2 scaffolds were implanted subcutaneously in mice for 4 and 8 weeks, and the
regenerated bone was analyzed with microcomputed tomography and histology; 8.6– 1.4mg BMP2 (22%) and
140– 29 IU EPO (69.8%) bound to the scaffold and < 1% BMP2 and 83% EPO was released in 7 days. Increased
endothelial cell proliferation on EPO-adsorbed PCL discs indicated protein bioactivity. At 4 and 8weeks, dual BMP2
and EPO delivery regenerated more bone (5.1–1.1 and 5.5–1.6mm3) than BMP2 alone (3.8– 1.1 and
4.3– 1.7mm3). BMP2 and EPO scaffolds had more ingrowth (1.4%– 0.6%) in the outer module when compared
with BMP2 (0.8%– 0.3%) at 4 weeks. Dual delivery produced more dense cellular marrow, while BMP2 had more
fatty marrow. Dual EPO and BMP2 delivery is a potential method to regenerate bone faster for prefabricated flaps.
Introduction
The gold standard for treating a large craniofacialbone defect is an autograft usually taken from the fibula
or iliac crest. This defect can be caused by trauma, tumor
resection, or developmental abnormalities. Methods to tis-
sue engineer a bone flap are under investigation to overcome
the drawbacks associated with autografts, including high
donor site morbidity, increased risk of infection, and defect
geometry mismatch. Tissue engineering a flap can be con-
ducted in vitro or in vivo. In vitro, the scaffold with added
cells would be placed in an external bioreactor. However,
regenerating a large bone volume (BV) in vitro is time-
consuming, and it is difficult to maintain optimal nutrient
perfusion throughout the scaffold.1 As an alternative, we
propose the process of prefabricating a bone flap in vivo by
implanting a patient-specific 3D-printed scaffold with as-
sociated biologics into the back muscle, and then trans-
planting it to the defect site after a maturation period as a
boney vascularized flap. Previous studies have created pre-
fabricated flaps by utilizing a titanium cage, filling it with
Bio-Oss blocks soaked in bone morphogenetic protein-7
(BMP7), adding cells, and implanting the construct inside of
the patient’s latissimus dorsi muscle.2–10 After 6 weeks, the
implant was transferred to the defect site, but due to loading
issues, the implant fractured and failed.2
We are looking to advance this prefabrication process by
integrating patient-specific design, 3D printing, and multiple
biologics delivery.11 Poly-e-caprolactone (PCL) is a bio-
compatible and biodegradable polymer, which can be 3D
printed using a selective laser sintering (SLS) manufacturing
technique to produce scaffolds of complex geometry based
on the patient’s computed tomography (CT) scan.12 SLS
printing can reproducibly create scaffolds with designed
porosity, mechanical properties, and permeability. Further-
more, PCL leads to less inflammation and generates less
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acidic by-products when compared with polylactic acid-
based copolymers.13 PCL is also currently utilized in 510(k)
approved cranioplasty bone filling applications.14,15 Pre-
viously, in our laboratory, we found that BMP2 adsorbed
onto a porous PCL scaffold in a clinically applicable setting
(1 h protein exposure at room temperature) regenerates bone
when implanted subcutaneously in a murine model.16
A flap needed for a large defect would need a large BV as
well as a rich vascular network to supply nutrients to the
growing bone, remove waste, and form a vascular pedicle
that can be connected to a vessel at the defect site. Fur-
thermore, for oncology patients awaiting adjuvant therapy,
the speed at which bone is regenerated in the donor muscle
site is essential. We hope to increase the regenerated BV at
an earlier time point when compared with BMP2 delivery
alone by delivering erythropoietin (EPO) along with the
BMP2 in a clinically applicable manner.
EPO is a protein that stimulates erythropoiesis, acts as a
cytokine for red blood cell precursors in the bone marrow,
and has been shown to promote angiogenesis in a variety of
tissues.17 EPO indirectly impacts bone healing by influ-
encing hematopoietic stem cells to produce BMP2.18–20 In
vitro, EPO has been shown to directly influence mesen-
chymal stem cells to differentiate into osteoblasts, indicating
that they must have EPO receptors.19,20 EPO receptors are
also expressed on endothelial cells, neurons, and trophoblast
cells.19 EPO has been used clinically to treat anemia and has
some angiogenic properties.21–23
EPO can be delivered systemically; however, drawbacks
include serious side effects, such as increased blood vis-
cosity, hypertension, and thromboembolic events.21,24,25 To
avoid the drawbacks associated with systemic delivery,
some studies have looked at local EPO delivery. Kobayashi
et al. delivered EPO using a gelatin hydrogel at the surface
of a rabbit heart,26 and Chen et al. delivered EPO using
fibrin gel to increase neovascularization.27 Interactions be-
tween EPO and BMP2 have been studied in vitro19,20 and
in vivo,28,29 and results have shown synergistic effects on
bone formation.
Although these dual delivery results are promising, there
is limited knowledge on the effects of locally delivering
both BMP2 and EPO on ectopic bone regeneration for
prefabricated flap applications. In addition, the use of 3D-
printed modular delivery of multiple growth factors has not
been reported. In this study, we investigated the in vitro
binding, release, and bioactivity of adsorbed BMP2 and
EPO from a modular PCL scaffold and, furthermore, ana-
lyzed the regenerated ectopic BV and spatial distribution.
Materials and Method
PCL scaffold fabrication
Solid PCL discs (6mm diameter, 2mm height) and 44%
porous inner (3.5mm sides, 4.3mm height, 106mm2 surface
area [SA]) and 79% porous outer (7mm sides, 4.3mm height,
357mm2 SA) PCL scaffolds were fabricated through SLS
using a Formiga P100 (EOS, Inc.) (Fig. 1). Previously, in this
laboratory, we used 70% porous scaffolds that had a different
geometry.16 Due to limitations, including laser spot size and a
new scaffold geometry requiring the two porous modules to
fit together tightly, two pore sizes were needed. PCL powder
(43–50kDa; Polysciences) was mixed with 4wt% hydroxy-
apatite (Plasma Biotal Limited). After manufacturing, the
scaffolds were air blasted, sonicated in 70% ethanol (EtOH),
sterilized in 0.22mm filtered 70% EtOH, and air-dried under
sterile conditions.
EPO binding to PCL scaffolds
One hundred micrograms of EPO (Creative Biomart) was
reconstituted in 1mL sterile Dulbecco’s phosphate-buffered
saline (DPBS) to result in 12,000 IU/mL (0.1mg/mL). The
stock solution was further diluted to the desired concentra-
tions in DPBS. The outer modular scaffolds were placed in
an ultra-low bind 24-well plate (Costar) and washed in
DPBS to wet the surface. Scaffolds were then exposed to
1mL EPO solution at room temperature for 1 h (n = 3);
100 IU/mL per PCL disc was used for bioactivity studies to
conserve materials, and 200 IU/mL per scaffold was used for
binding, release, and in vivo studies. Finally, scaffold
modules were washed in DPBS to remove loosely bound
protein. The washes and the remaining EPO solution fol-
lowing the exposure were collected to indirectly quantify the
EPO remaining in the solution utilizing a protein quantifi-
cation kit (Fluoroprofile; Sigma). A standard curve was
created from 2.5 to 0 mg/mL (300–0 IU/mL). A volume of
FIG. 1. Modular scaffold assem-
bly. BMP2 was adsorbed onto the
inner scaffold module and EPO
was adsorbed onto the outer scaf-
fold module. The two scaffolds
were then assembled. BMP2, bone
morphogenetic protein-2; EPO,
erythropoietin.
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working solution (Fluoroprofile reagent and buffer) was
added to an equal volume of unknown EPO sample. Sam-
ples were read in triplicates with a fluorometric reader
(520 nm excitation, 620 emission).
EPO Bound (IU)¼ (EPO exposed to scaffold)
 (EPO in remaining solution
þEPO in washes)
BMP2 binding and quantification
BMP2 was adsorbed onto the inner scaffold modules as
previously described.16 Briefly, 1mg lyophilized BMP2
(BMP2-01H; Creative Biomart) was dissolved in 1mL of
20mM acetic acid and it was then further diluted in BuPH
(No. 28372; Pierce) buffer with 0.1M EDTA (pH 7.0) to
65 mg/mL. A BMP2 ELISA (Peprotech), specific for Es-
cherichia Coli-derived BMP2, was used to quantify the
protein content in the 65 mg/mL BMP2 solution (average
detected concentration was 28.12 – 4.6 mg/mL) and the
binding studies were normalized to this value. Briefly, the
inner scaffold modules were washed in BuPH buffer (pH
7.2), followed by BuPH + 0.1M EDTA buffer to wet the
surface, exposed to 1mL of 65 mg/mL BMP2 for 1 h at 23C
(n = 3), and washed in water (diH2O) before use. The washes
and the BMP2 solution remaining after exposure were col-
lected, 1% bovine serum albumin (BSA) was added to result
in 0.1% BSA content, and samples were stored at -80C
until ELISA analysis for BMP2 content.
BMP2 Bound (lg)
¼ (BMP2 in original solution detected by ELISA)
 (BMP2 in remaining solution þ BMP2 in washes)
The ELISA was carried out according to the manufacturer’s
directions.
Release kinetics
The outer scaffold modules with adsorbed EPO were
manually assembled with the inner scaffold modules that had
no BMP2 adsorbed (Fig. 1). Constructs were submerged in
1mL DPBS and incubated at 37C, 95% humidity, 5% CO2.
The supernatant was collected and replenished at 1, 2, 3, 5,
and 7 days after initial exposure. Samples were stored at
-80C until Fluoroprofile assay analysis for protein content.
The inner scaffold modules with adsorbed BMP2 were
assembled with an outer module that had no adsorbed EPO,
submerged in 1mL DPBS, and incubated at 37C, 95%
humidity, 5% CO2. The supernatant was collected and re-
plenished 1, 2, 3, 5, and 7 days after initial exposure. Su-
pernatants with a final 0.1% BSA content were stored at
-80C until BMP2 quantification with an ELISA.
Adsorbed EPO bioactivity
Previous studies in the laboratory show that BMP2 ad-
sorbed to the PCL surface maintains bioactivity as seen by
C2C12 cell alkaline phosphatase production.16 In this study,
endothelial cell proliferation was used to indicate EPO
bioactivity as done in other studies.30–32 A disc geometry
with a flat surface was used for this assay due to a well-
defined surface area and a simple geometry. This assay’s
goal was to assess the protein’s bioactivity and not the ex-
tent of bioactivity. Second passage human umbilical vein
endothelial cells (HUVECs) were cultured in EGM-2
growth medium (CC-3162; Lonza) for 4 days at 37C, 95%
humidity, 5% CO2. Cells were trypsinized using 0.05%
Trypsin with EDTA (Gibco) and quantified with an auto-
matic cell counter—MoxieZ (Orflo).
EGM-2 growth media (1mL) were added to PCL discs
exposed to 100 IU EPO (n = 4), and 2.0 · 104 HUVECs were
seeded on each disc (11,765 cells/cm2). Cells seeded onto
discs without EPO exposure and PCL discs without cells
served as the negative control. After 72 h of static culture,
the cell medium was replaced with 500 mL of fresh EGM-2
medium and 100mL of MTS solution (CellTiter96 Aqueous
One Solution; Promega) was added per well. Constructs
were incubated with the MTS reagent at 37C for 4 h and
triplicates for each condition were read at 490 nm on a
microplate reader.
Cells were also seeded at 0, 2· 104, 4·104, 8·104, and
16· 104 cells per well in triplicate to create a standard curve
(cell number vs. absorbance reading). After 1 h, 100mL ofMTS
solution was added to the 500mL EGM medium in each well,
and the absorbance was read at 490nm on a microplate reader.
In vivo bioactivity: subcutaneous implantation
BMP2 inner scaffold modules (adsorbed with 65mg/mL
BMP2) were assembled with outer scaffold modules (ad-
sorbed with 200 IU/mL EPO) for the dual delivery BMP2+
EPO group. The negative control was outer modules with
200 IU/mL EPO adsorbed and no BMP2 adsorbed onto the
inner modules (EPO group). The positive control was inner
modules with 65mg/mL BMP2 adsorbed and no EPO ad-
sorbed onto the outer modules (BMP2 group). Scaffolds
from each group were implanted subcutaneously in 5- to 6-
week-old female C57BL/6N mice.
The dorsal hair was shaved and an incision was made in
the back. Two subcutaneous pockets were created, one on
each side, and a scaffold was placed into each pocket.
Scaffolds were randomly assigned a side to be implanted
such that half of the samples from each group were im-
planted on both the right and left sides. The positive control
(the BMP2 group) was implanted in a parallel study such
that BMP2 +EPO and BMP2 scaffolds were not implanted
in the same mouse. Mice were sacrificed at 4 and 8 weeks
postsurgery to assess bone regeneration. The explanted
specimens were placed in Z-Fix (Anatech) overnight, wa-
shed in diH2O for 24 h, and stored in 70% EtOH until assays
were performed. Table 1 describes the total sample numbers
and the number of samples used for each specific analysis
method. This study was conducted in compliance with the
regulations set forth by the University Committee on Use
and Care of Animals at the University of Michigan.
Microcomputed tomography
Fixed scaffolds were scanned in water with a high-reso-
lution (16mm) micro-CT (microCT) scanner (Scanco Med-
ical), and the scans were calibrated to Hounsfield units
(HU). BV was defined at a 1050HU threshold using Mi-
croview software (Parallax Innovations). Tissue mineral
BMP21EPO DELIVERY FROM MODULAR PCL SCAFFOLD REGENERATES BONE 891
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density (TMD) was determined using exported grayscale
data. The total scaffold region was represented as a cubical
region of interest (ROI) defined as 7· 7 · 4.3mm height. An
ROI defining the inner scaffold module (3.5 · 3· 4.3mm
height) was used to determine bone formation within the
module. Bone regenerated in the outside scaffold module
was calculated as the inner scaffold module BV subtracted
from the total scaffold BV. The total, inner module, and
outer module scaffold bone ingrowth was calculated as the
BV divided by the available pore volume in each region.
Available pore volume was calculated from the porosity of
each module based on the microCT image of an assembled
modular scaffold (preimplantation) scanned in air. To de-
termine the amount of bone formed in the central region of
the inner module pores instead of on the PCL surface, a
0.6750-mm-diameter, 4.3-mm-height cylinder ROI was
created in all four vertical pores, and the total BV in inner
module pores was calculated. TMD was calculated for the
total, inner module, and outer module scaffolds.
Histology
Fixed scaffolds from each group were decalcified with
RDO (Apex Engineering Products Corporation), processed,
and embedded in paraffin. Samples were then sectioned at
7mm thickness using a MICRON HM 325 (Thermo Scien-
tific) and slides were incubated at 37C overnight to dry.
Sections were stained with hematoxylin and eosin (H&E) to
visualize cells, tissue matrix, blood vessels, and general tissue
morphology. Sections were imaged with a 4· objective.
Statistical analysis
Data are expressed as mean – standard deviation of the
mean. An analysis of variance was used to determine sta-
tistical significance between groups. A p-value less than
0.05 (a <0.05) was considered statistically significant on a
95% confidence interval.
Results
Protein binding and release kinetics
After 1 h of protein exposure, 139.6 – 28.6 IU EPO
(69.8%) and 8.56 – 1.4 mg BMP2 (22%) bound to the outer
and inner scaffold modules, respectively. After 7 days,
0.0311 – 0.0053mg BMP2 (<1%) and 119.2 – 29.4 IU EPO
were released (85%) from the PCL surface (Fig. 2A, C). For
both proteins, there was a relatively small burst release in
the first 2 days of 45.8 – 24 IU EPO (32.8%) and 0.017–
0.007 mg BMP2 (0.2%) (Fig. 2B, D). HUVECs seeded on
EPO-adsorbed PCL discs experienced increased cell pro-
liferation (2.4– 0.3 · 104 cells/disc) when compared with
Table 1. Sample Numbers for In Vivo Analysis.
Number of Samples Used in Explanted
Specimen Analysis Methods
lCT scan Histology Total samples
Group 4 week 8 week 4 week 8 week 4 week 8 week
BMP2 +
EPO
9 8 3 2 9 8
BMP2 8 9 2 2 8 9
EPO 9 8 3 2 9 8
FIG. 2. Protein release profiles.
(A) BMP2 cumulative release pro-
file. After 7 days, 0.0311– 0.0053mg
BMP2 was released into phosphate-
buffered saline at 37C. (B) BMP2
release. A small burst release oc-
curred in the first 2 days, followed by
sustained release. (C) EPO cumula-
tive release profile. After 7 days,
119.2– 29.4 IU of the 139.6–
28.6 IU that was bound was released.
(D) EPO released over 7 days with a
small burst release in the first 2 days.
(n= 3/group).
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cells seeded on PCL discs without any protein exposure
(1.6 – 0.1 · 104 cells/disc) (Fig. 3).
Microcomputed tomography: bone volume
Visual analysis of the microCT scans shows that BMP2
only groups regenerated bone (indicated by the red arrow)
localized mainly on the inner module, which had been ad-
sorbed with the osteogenic factor (Fig. 4A). The darker ar-
eas are the pore space indicated by the red circle, and the
light gray areas are the PCL scaffold (red star). The
BMP2 +EPO group regenerated bone not only in the inner
module but also in the surrounding outer module. At both
time points, the dual delivery BMP2 +EPO group produced
more bone than the BMP2 group. The EPO group re-
generated little to no visible bone. Microview software was
utilized to quantify the BV observed in the microCT scans.
At 4 weeks, the dual delivery group regenerated signifi-
cantly more total bone (5.1 – 1.1mm3) than the BMP2 group
(3.8 – 1.1mm3) ( p= 0.019) (Fig. 4B). BMP2 +EPO had
more bone regenerated in the inner module, although it was
not significantly more ( p = 0.068), and in the outer module
( p = 0.276). At 8 weeks, a similar trend was observed;
however, there was no significant difference between dual
and single growth factor delivery (p=0.279). Overall, BMP2+
EPO regenerated more total, inner module, and outer module
BV than the BMP2 group. At both time points, the BMP2 and
BMP2+EPO groups had significantly more BV than the EPO
group (less than 0.2mm3).
Bone ingrowth and TMD analysis
Bone ingrowth analysis was not conducted for the EPO
group because little to no BV was detected. At 4 and 8
weeks, both of the BMP2 +EPO and BMP2 groups had the
same BV form in the inner module pores (Fig. 5A). At 4
weeks, BMP2 +EPO had significantly more bone ingrowth
in the outer module (1.44%– 0.6%) when compared with
the BMP2 group (0.81% – 0.3%) ( p= 0.018) (Fig. 5B). The
increased bone ingrowth for dual delivery also occurred at 4
weeks in the inner module; however, the increase was not
significant ( p = 0.067). With respect to the total scaffold,
BMP2 +EPO had significantly more ingrowth than BMP2 at
4 weeks ( p = 0.03). There were no significant differences in
ingrowth between the two groups throughout the scaffold at
8 weeks (Fig. 5B).
TMD analysis showed that regenerated bone in the BMP2
group was significantly more mineralized than that of the
BMP2 +EPO group at 4 weeks (505.8– 31.1 vs. 440.18 –
29.1mg HA/cm3; p = 0.0001) and at 8 weeks (583.0 – 35.7
vs. 501.7 – 40.6mg HA/cm3; p = 0.001). Further analysis of
inner and outer scaffold module TMD at 4 weeks showed
that the BMP2 group had significantly more dense bone in
the outer module when compared with the inner module.
The BMP2 +EPO group had no difference in TMD between
the two scaffold modules. At 8 weeks, both BMP2 and
BMP2 +EPO groups had uniform TMD throughout the
scaffold (Fig. 6).
Histology
Histology staining showed bone marrow, osteoid, blood
vessels, and osteocytes embedded in bone matrix for the
FIG. 3. Adsorbed EPO bioactivity. HUVECs seeded on
the PCL disc exposed to EPO showed increased levels of
proliferation. n = 4; *p < 0.05. HUVEC, human umbilical
vein endothelial cells; PCL, poly-e-caprolactone.
FIG. 4. MicroCT analysis of regenerated bone. (A) Re-
presentative microCT images. The BMP2 group regenerated
bone localized to the inner module, and EPO+BMP2 re-
generated bone in the outer module pores aswell as in the inner
module. Red arrow= bone, red circle= pore space, red star=
PCL scaffold. (B) EPO+BMP2 resulted in significantly more
total regenerated bone compared with the BMP2 group at 4
weeks (*p< 0.05). MicroCT, microcomputed tomography.
Color images available online at www.liebertpub.com/tec
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BMP2 +EPO and BMP2 groups (Fig. 7). The dual delivery
group had more dense cellular marrow and the BMP2 group
seemed to have more fatty marrow. The EPO group com-
prised mostly fibrous tissue. For both groups, osteocytes
were embedded in the osteoid and osteoblasts were located
at the periphery of forming bone.
Discussion
Medtronic’s Infuse product has been FDA approved for
BMP2 delivery from a collagen type 1 sponge for a variety
of applications: spinal fusion, the treatment of open tibial
fractures, sinus augmentation, and dental procedures.33 Due
to the BMP2 short half-life, a 1.5mg/mL BMP2 dose was
needed (greatly exceeding native concentrations of 18.8–
22 pg/mL), which resulted in a large burst release during the
first 2–3 days causing adverse reactions in some patients.34
Amgen’s product EPOGEN is also FDA approved and
uses the EPO protein to increase red blood cell levels caused
by chronic kidney disease in anemic patients. This admin-
istration avoids the need for red blood cell transfusions.35,36
Since these proteins are already FDA approved, the next
step of dual delivery is feasible, although some regulatory
hurdles would increase.
Although local BMP2 delivery from various scaffolds in a
subcutaneous model has been widely studied for bone tissue
engineering applications, there are very few investigations
into local EPO delivery. EPO has been delivered through
injectable hydrogels,37,38 gelatin,26 and fibrin gel27 for an-
giogenesis studies; however, only one study of which we are
aware has locally delivered EPO and BMP2 from a porogen-
leached protein microbubble polyglycolic acid (PLGA)
scaffold to assess bone regeneration in a calvarial defect
model.29 In another study, BMP2 was delivered from a col-
lagen scaffold implanted in a rat calvarial defect, and EPO
was injected subcutaneously at the defect site every other day
for 2 weeks. After 6 weeks, the dual delivery group had a
higher BV fraction than the BMP2 alone group.28 There is
limited to no knowledge of the binding and release of ad-
sorbed EPO on PCL and, furthermore, the effect of dual EPO
and BMP2 delivery on bone regenerated in an ectopic loca-
tion for the application of prefabricated flaps is unknown.
In this study, we used adsorption as the protein-binding
method to PCL due to the potential translational nature of
this process. A short protein exposure time (<1 h) at room
temperature before scaffold implantation is ideal for oper-
ating room environments. More complex processes that bind
the protein outside of the operating room will face increased
regulatory hurdles, such as sterilization, shelf life, and main-
tained efficacy studies. Additionally, in this study, a modular
scaffold design is used, which is a novel method to deliver
multiple growth factors. The two components are simple to
assemble while maintaining their geometric complexity due
to SLS manufacturing.
One hour adsorption resulted in 139.6 – 28.6 IU EPO
(69.8%) and 8.56– 1.4 mg BMP2 (22%) binding. After 7
days, less than 1% BMP2 was released. Even though this is
a small amount, it is shown to be therapeutically relevant in
the in vivo study. Since an ELISA was used to detect the
protein, the remaining BMP2 could have released off the
surface, but may have degraded, which would go undetected
by the assay. Another explanation is that it may not have
been released and required in vivo proteolytic activity to be
released. As for EPO, 85% of the bound protein was re-
leased in the first week in vitro. Similarly, Fayed et al. in-
corporated EPO into PLGA nanoparticles, resulting in a
33% loading efficiency and 82% release over 24 h.39 When
delivered from chitosan nanoparticles, 30% was released in
the first 48 h, and a total of 63% was released over 15 days
in phosphate-buffered saline at 37C.40 EPO adsorbed onto
dialysis bags resulted in less than 7% binding.41 HUVECs
proliferated significantly more on PCL discs with adsorbed
EPO, indicating that the bound or released EPO was still
bioactive. We have shown in previous studies that BMP2
released after adsorption onto PCL was still bioactive, as
seen with alkaline phosphatase activity.16 BMP2 was
FIG. 5. Pore bone growth and
scaffold ingrowth. (A) Bone vol-
ume formed inside of the inner
module vertical pores was quanti-
fied at a 1050HU threshold. Pore
ROIs used were 4.3mm in height,
0.670mm in diameter. (B) Dual
delivery had higher bone ingrowth
in the total, inner module, and outer
module at 4 weeks (*p < 0.05). HU,
Hounsfield units; ROI, region of
interest.
FIG. 6. TMD analysis of regenerated bone. TMD of the
total, inner module, and outer module was determined using
Microview software. At 4 weeks, the BMP2 group had more
dense bone in the outer module and the dual delivery group
had the same density bone throughout the scaffold
(*p < 0.05). TMD, tissue mineral density.
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adsorbed onto the inner module because it is more chal-
lenging to regenerate bone at the scaffold’s center. EPO is
known to have angiogenic effects, and with its relatively
faster release profile, developing vasculature in the outer
module could deliver more cells to the BMP2 located at the
center of the scaffold.
In vivo, a modular scaffold that delivered EPO combined
with BMP2 produced significantly more total bone at 4
weeks when compared with the BMP2 group. This increased
early bone formation is important for prefabricated flap
applications because the flap would mature faster for on-
cology patients awaiting adjuvant therapy. At 8 weeks, the
dual delivery group still had more bone than the BMP2 alone
group; however, the increase was not significantly different.
Upon visual inspection, the BMP2 group regenerated bone
localized to the inner module area where the BMP2 was
adsorbed. The BMP2+EPO group regenerated bone in both
the outer and inner modules, indicating that the EPO influ-
ence was not spatially constricted to the outer module. It may
have had a synergistic effect on bone production in adjacent
areas. Since EPO was released rather quickly, it could have
diffused to interact with migrating cells. Bone formation was
also controlled and limited within the scaffold boundary.
Dual delivery produced more bone than the BMP2 group, but
the amount of bone that grew in the inner module pores was
the same; therefore, dual delivery may have grown more bone
on the surface of the pores.
Bone ingrowth analysis found that BMP2+EPO re-
generated significantly more bone in the outer module
available pore space at 4 weeks when compared with BMP2
alone. This increased bone growth seen with the dual delivery
group could be explained by the synergistic effects between
EPO and BMP2. EPO has shown to play a role in osteo-
clastogenesis and osteoclasts can recruit mesenchymal stem
cells to the site of bone remodeling.28 If EPO caused an initial
increase in osteoclast numbers, this may have resulted in
increased bone-forming cells recruited to the construct. In-
terestingly, although dual delivery had more bone than the
BMP2 group, the BMP2 group had a higher TMD when
compared with BMP2+EPO at both time points. One po-
tential explanation for this difference could be that the dual
delivery bone was forming faster than BMP2 alone and the
osteoblasts may not have been mineralizing the osteoid at the
same rate. Despite the difference, dual delivery resulted in
uniform TMD throughout the scaffold in the range of native
bone, whereas BMP2 had more dense bone in the outer
module when compared with the inner module. With regard
to developing a bone flap, having more bone with TMD in the
normal range may be an advantage over less bone with higher
mineral content overall. Gross tissue morphology analysis of
explanted samples finds a more dense cellular marrow for the
BMP2+EPO groups and a more fatty marrow for the BMP2
groups. This difference should be further investigated in fu-
ture studies.
In this study, we successfully detected adsorbed EPO and
BMP2 binding and release kinetics from a novel modular
PCL scaffold. Once adsorbed to the surface, these proteins
maintain bioactivity. These two proteins are already FDA
approved for several clinical indications, and the simple
binding process can be conducted in a clinically applicable
environment (1 h of protein to scaffold exposure at room
temperature). Furthermore, delivering EPO along with the
osteogenic protein BMP2 resulted in increased bone regen-
eration in comparison with single BMP2 or EPO delivery.
Since the implant is acellular when implanted, circulating
mesenchymal stem cells and fibroblasts could be interacting
with the delivered growth factors and inducing bone forma-
tion. Future studies should investigate the effects of altering
the BMP2 and EPO dose ratios, and more studies could be
completed to elucidate the mechanisms of EPO and BMP2
synergy to further optimize the dual delivery protocol.
Conclusions
The speed at which bone forms in a prefabricated flap is
crucial for oncology patients awaiting adjuvant therapy. In
this study, we have found that delivering EPO along with
BMP2 could be a potential method to regenerate a greater
BV at an earlier time point when compared with BMP2
alone delivery. Local dual delivery of EPO and BMP2 has
not been investigated in depth, and delivering multiple bi-
ologics may advance the process of prefabricating flaps for
skeletal reconstruction.
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